Effect of Sacubitril Valsartan Combined with Dapagliflozin in the Treatment of Patients with HFrEF
Objective:To observe the effect of Sacubitril Valsartan combined with Dapagliflozin in the treatment of patients with heart failure with reduced ejection fraction(HFrEF).Method:Two hundred patients with HFrEF who admitted to Macheng People's Hospital from May 2021 to May 2022 were selected as the study objects,and they were divided into the combination group(n=101)and the control group(n=99)by random number table method.All patients were given routine anti-heart failure treatment and intervention,the control group was given Sacubitril Valsartan,and the combination group was given Dapagliflozin on the basis of the control group.The efficacy,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)],T lymphocyte subsets(CD3+,CD8+,CD4+/CD8+)before and after treatment,adverse reactions and heart failure rehospitalization rate were compared between two groups.Result:The total effective rate in the combination group was 95.05%,which was higher than 81.82%in the control group,the difference was statistically significant(P＜0.05);after treatment,the LVEF,CD3+and CD4+/CD8+in two groups were higher than those before treatment,and those in the combination group were higher than those in the control group,the LVESD,LVEDD,hs-CRP,TNF-α,IL-6 and CD8+in two groups were lower than those before treatment,and those in the combination group were lower than those in the control group,the differences were statistically significant(P＜0.05);there was no significant difference in the incidence of adverse reactions between two groups(P＞0.05);the heart failure rehospitalization rate in the combination group after 12 months of follow-up was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion:Sacubitril Valsartan combined with Dapagliflozin in the treatment of patients with HFrEF can effectively improve the efficacy and cardiac function,reduce inflammatory factors level,improve immune function,and reduce the heart failure rehospitalization rate,with good safety.
Heart failure with reduced ejection fractionSacubitril ValsartanDapagliflozin
万方数据
维普
